CEPI unveiled how it is applying AI to pandemic prediction through an effort aimed at meeting a “100-day mission” after identifying a pandemic threat. Speaking at BioProcess International Europe 2026 in Vienna, vaccine expert Renske Hesselink outlined how CEPI plans to use AI across vaccine development guidance, manufacturing and supply-chain planning, and threat identification. CEPI’s message ties lessons from COVID-19 to the goal of accelerating the earliest actions that determine whether vaccine programs can reach scale before transmission peaks. Hesselink framed the initiative as an AI-powered platform that can act as a data-sorting and hypothesis-testing support tool for developers. For biopharma organizations, the operational focus is on reducing bottlenecks from target selection through manufacturing scaling, where timeline compression depends on both decision tools and practical execution planning.